Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

A. Ravelli; B. Ramenghi; G. Di Fuccia; N. Ruperto; L. Zonta; A. Martini

Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

A. Ravelli, B. Ramenghi, G. Di Fuccia, N. Ruperto, L. Zonta, A. Martini

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

We retrospectively investigated, in 19 children with systemic-onset juvenile chronic arthritis (SoJCA), the possible influence on the outcome of methotrexate (MTX) therapy of several independent variables, including age at onset of juvenile chronic arthritis, disease duration and severity of the disease at baseline. The dosage of MTX ranged from 7.5 to 11.0 mg/m²/week (median 9.3 mg/m²/week) and was given as a single, oral weekly dose. After 6 months of treatment, 12 (63%) patients were judged as responders on grounds of a ≥ 50% reduction in the number of joints with active arthritis and/or an articular severity score; 7 (37%) did not respond to therapy. When the baseline values of the selected variables were compared, we found that the responder group had, with respect to the non-responder group, a lower percentage of radiographic lesions (p

Original language	English
Pages (from-to)	428-432
Number of pages	5
Journal	Acta Paediatrica, International Journal of Paediatrics
Volume	83
Issue number	4
Publication status	Published - 1994

Keywords

Disease duration
Juvenile chronic arthritis
Methotrexate
Radiographic lesions
Treatment outcome

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis'. Together they form a unique fingerprint.

Cite this

@article{3618e97d921d4a34ac2d3e647ac82b0a,

title = "Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis",

abstract = "We retrospectively investigated, in 19 children with systemic-onset juvenile chronic arthritis (SoJCA), the possible influence on the outcome of methotrexate (MTX) therapy of several independent variables, including age at onset of juvenile chronic arthritis, disease duration and severity of the disease at baseline. The dosage of MTX ranged from 7.5 to 11.0 mg/m2/week (median 9.3 mg/m2/week) and was given as a single, oral weekly dose. After 6 months of treatment, 12 (63%) patients were judged as responders on grounds of a ≥ 50% reduction in the number of joints with active arthritis and/or an articular severity score; 7 (37%) did not respond to therapy. When the baseline values of the selected variables were compared, we found that the responder group had, with respect to the non-responder group, a lower percentage of radiographic lesions (p",

keywords = "Disease duration, Juvenile chronic arthritis, Methotrexate, Radiographic lesions, Treatment outcome",

author = "A. Ravelli and B. Ramenghi and {Di Fuccia}, G. and N. Ruperto and L. Zonta and A. Martini",

year = "1994",

language = "English",

volume = "83",

pages = "428--432",

journal = "Acta Paediatrica, International Journal of Paediatrics",

issn = "0803-5253",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

AU - Ravelli, A.

AU - Ramenghi, B.

AU - Di Fuccia, G.

AU - Ruperto, N.

AU - Zonta, L.

AU - Martini, A.

PY - 1994

Y1 - 1994

N2 - We retrospectively investigated, in 19 children with systemic-onset juvenile chronic arthritis (SoJCA), the possible influence on the outcome of methotrexate (MTX) therapy of several independent variables, including age at onset of juvenile chronic arthritis, disease duration and severity of the disease at baseline. The dosage of MTX ranged from 7.5 to 11.0 mg/m2/week (median 9.3 mg/m2/week) and was given as a single, oral weekly dose. After 6 months of treatment, 12 (63%) patients were judged as responders on grounds of a ≥ 50% reduction in the number of joints with active arthritis and/or an articular severity score; 7 (37%) did not respond to therapy. When the baseline values of the selected variables were compared, we found that the responder group had, with respect to the non-responder group, a lower percentage of radiographic lesions (p

AB - We retrospectively investigated, in 19 children with systemic-onset juvenile chronic arthritis (SoJCA), the possible influence on the outcome of methotrexate (MTX) therapy of several independent variables, including age at onset of juvenile chronic arthritis, disease duration and severity of the disease at baseline. The dosage of MTX ranged from 7.5 to 11.0 mg/m2/week (median 9.3 mg/m2/week) and was given as a single, oral weekly dose. After 6 months of treatment, 12 (63%) patients were judged as responders on grounds of a ≥ 50% reduction in the number of joints with active arthritis and/or an articular severity score; 7 (37%) did not respond to therapy. When the baseline values of the selected variables were compared, we found that the responder group had, with respect to the non-responder group, a lower percentage of radiographic lesions (p

KW - Disease duration

KW - Juvenile chronic arthritis

KW - Methotrexate

KW - Radiographic lesions

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0028269801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028269801&partnerID=8YFLogxK

M3 - Article

C2 - 8025404

AN - SCOPUS:0028269801

VL - 83

SP - 428

EP - 432

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 4

ER -

Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this